ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
C09DB01 | G | Amlodipine - 5mg, Valsartan - 160mg | 7311 | 186372/13 | LOTEVAN | 30 | Tablet, film coated | Oral | Mersaco | Tabuk Pharmaceutical Manufacturing Company | Saudi Arabia | 857,372 L.L | 23.08 | A2 | Tabuk Pharmaceutical Manufacturing Company | Saudi Arabia | 2/5/2024 | 0 |
ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
C09DB01 | B | Amlodipine - 5mg, Valsartan - 160mg | 11777 | 137823/1 | EXFORGE | 28 | Tablet, film coated | Oral | Khalil Fattal & Fils S.A.L. | Novartis Farma SpA | Italy | 1,333,092 L.L | 23.08 | A2 | Novartis Pharma AG | Switzerland | 2/5/2024 | 0 | |
C09DB01 | G | Amlodipine - 5mg, Valsartan - 160mg | 8033 | 24814/1 | ARBITEN AM 5/160 | 30 | Caplet, film coated | Oral | Eva Pharm Plus | Joswe Medical (Jordan Sweden Medical and Sterilization Co) | Jordan | 857,372 L.L | 23.08 | A2 | Joswe Medical (Jordan Sweden Medical and Sterilization Co) | Jordan | 2/5/2024 | 0 | |
C09DB01 | G | Amlodipine (besylate) - 5mg, Valsartan - 160mg | 9801 | 116416/1 | POVAM | 30 | Tablet, film coated | Oral | Premium Serve Drugstore Co. P.S.D. SAL | The United Pharmaceutical Manufacturing Co Ltd | Jordan | 857,372 L.L | 23.08 | A2 | The United Pharmaceutical Manufacturing Co Ltd | Jordan | 2/5/2024 | 0 | |
C09DB01 | G | Amlodipine besylate - 5mg, Valsartan - 160mg | 10350 | 166818/1 | VIOSTAN AM 160/5 | 30 | Tablet, film coated | Oral | Benta Trading Co s.a.l. | Benta SAL | Lebanon | 1,177,206 L.L | 23.08 | B | 2/5/2024 | 0 |